We have previously reported studies identifying the molecular bases of inhalation and i.v. anaesthetic immobilizing activity using the ligand-based molecular modelling technique, comparative molecular field analysis (CoMFA). 1 -4 In CoMFA, the steric and electrostatic interaction energies between the anaesthetic molecules and a charged probe atom are calculated and correlated with potency to formulate an activity model. Pharmacophoric maps can be derived to highlight the spatial distribution of key regions where the steric and electrostatic interactions are making the greatest contribution to the activity model. Cardiovascular depression is an important side-effect of most anaesthetics, but the molecular properties that determine this activity are unknown. The present study aimed to identify the molecular basis for in vivo cardiovascular depression seen during i.v. continuous infusion anaesthesia and to compare the resulting pharmacophore maps with the equivalent models for in vivo immobilizing activity.
Methods
Thirteen structurally diverse i.v. general anaesthetic agents were considered [eltanolone (5b-pregnanolone), alphaxalone, minaxolone, ORG 21465 (a water-soluble dimethylmorpholin-4-yl, 5a-pregnane steroid), thiamylal, thiopental, methohexital, pentobarbital, rac-ketamine, R-etomidate, ORG 25435 (an a-amino acid phenolic ester derivative), clomethiazole, and propofol].
Cardiovascular activity
Haemodynamic data during continuous infusion anaesthesia, measured as the mean arterial pressure (MAP), were taken from the literature 5 -33 together with additional unpublished data from the author. All measurements were made under conditions of steady-state anaesthesia, with the arterial pressure calculated as the per cent change from arterial pressure during the pre-anaesthetic awake state and the associated plasma-free drug concentrations. In all studies, the arterial pressure changes were noted at times of no surgical or other noxious stimulation.
Two different measures of cardiovascular activity were determined. The first model compared the plasma-free anaesthetic concentration that resulted in a 20% decrease in MAP (dMAP 20 ). Since infusions of ketamine are associated with an increase in arterial pressure, haemodynamic data for ketamine were excluded from this analysis, with the final model being derived for the other 12 agents.
Data used for this cardiovascular model were the results of individual plots of free drug concentration vs change in MAP (%) compared with the pressure recorded in the awake state for each of the studies referenced. The mean dMAP 20 (as shown in Fig. 1 ) was calculated from the linear regression equation of log drug concentration and per cent change in MAP for each anaesthetic. As such, values in Figure 1 represent point estimates. Data were obtained from both human and non-human (dog, pig, or both) studies for alphaxalone, etomidate, thiopental, methohexital, and propofol. Cardiovascular data for pentobarbital and thiamylal were obtained from studies in the dog. Where data from different species were available, comparison was made of the separate estimates for dMAP 20 for each species.
A second cardiovascular model was formulated based on the absolute change (increase or decrease) in MAP when the i.v. anaesthetic was infused at the EC 50 drug concentration (the free drug plasma concentration of anaesthetic that abolishes movement in response to noxious stimuli in 50% of patients). Data for 13 i.v. agents (the 12 in the previous model plus rac-ketamine) were included.
Immobilizing activity
Potency data (expressed as the EC 50 plasma-free drug concentration that abolishes movement in response to noxious stimuli) together with data for protein binding were obtained from the literature and have been reported previously. 2 Wherever possible, data were taken from studies in which no other adjuvant drugs were administered up to the time of the stimulus (either the initial surgical incision for human studies or the response to comparable noxious stimulus in animal studies). Where 67% nitrous oxide was given as part of the anaesthetic, this was assumed to equate to 0.6 MAC.
For the comparison of changes in MAP at the EC 50 drug concentration, data from individual studies were collated, and again mean values are shown as point estimates in Table 1 . 
Molecular model construction
Computer-based models of the anaesthetics, calculation of the anaesthetics three-dimensional (3D) physicochemical properties, and derivation of the CoMFA activity models and pharmacophoric maps were performed using the molecular modelling software SYBYL v7.3 (Tripos Inc., St Louis, MI, USA) on a Silicon Graphics O2 R10000 workstation. 2 All compounds were modelled in their unionized state.
For each anaesthetic, a set of low energy conformers were identified by a random search procedure in SYBYL. Only geometry optimized conformers with a potential energy within þ4 kcal mol 21 of the lowest energy conformer of a given anaesthetic were retained. Since the probability of a specific conformer occurring is related to the potential energy of the structure, the applied limit ensured that only realistic configurations of the anaesthetics were considered. The process was repeated until each anaesthetic had been subjected to 10 000 random structure perturbations or until each of the low energy conformers had been found at least 12 times.
Structure alignment
Since the chemical diversity of the i.v. anaesthetics precludes their alignment by a common substructure, the low energy conformers were aligned for CoMFA by field-fit minimization 34 35 to provide the best correlation between the steric and electrostatic fields of the molecules and those of a single-lead structure, the same conformer of eltanolone as used in the previous studies. 
CoMFA formulation
Separate CoMFA models were derived for the two aspects of anaesthetic activity using the SYBYL software package. The aligned structures were placed in a grid consisting of lattice points at 1 Å intervals. An sp3 carbon atom and a charge of þ1.0 were used as probes to generate the steric and electrostatic interaction energies between the probe and the anaesthetic molecules at each lattice point. Steric energies were calculated using a Leonard -Jones 6 -12 potential, which describes the attraction between molecules due to van der Waals forces (dispersion, dipole-induced dipole, and dipole -dipole interactions) and repulsion due to steric clashes. Electrostatic interaction energies were calculated using Coulomb potentials with a distancedependent dielectric function. The default cut-off value of 30 kcal mol 21 was applied to both steric and electrostatic energies. A separate CoMFA analysis was performed for each aspect of activity. The orientations of the anaesthetics that yielded CoMFA models with the greatest predictive capability (assessed by leave-one-out cross-validation) were retained.
The use of 1 Å grid intervals represents a compromise between accuracy and the introduction of 'noise' from sampling irrelevant data. The grid extended at least 4 Å beyond the surface of the molecules, and comprised a total of 9025 lattice points.
Activity model formation
Activity models were formulated using partial least squares regression analysis to correlate the interaction energies at each lattice point with the immobilizing or cardiovascular activities of the anaesthetics. 36 In this process, orthogonal latent variables are formed from a weighted combination of the steric and electrostatic interaction energies at each lattice point. The magnitude of the individual weighting coefficients within the latent variables indicates the relative importance of the steric or electrostatic energy at each lattice point. Specific regions in the resulting 3D models where steric and electrostatic interactions are important can be identified and plotted to derive pharmacophoric maps.
Two approaches were employed to determine the intrinsic predictive power of the CoMFA models. First, the models were assessed using leave-one-out crossvalidation. 37 In this process, activity models were repeatedly reformulated by leaving one compound out of the model at each stage. The model with the greatest crossvalidated r 2 (q 2 ) was retained as the final model. The activity models were further assessed using crossvalidation with four compounds randomly excluded at each stage. These cross-validation studies were each run for 10 cycles and mean values (mCV4q 2 ) (SD) calculated.
Results
Cardiovascular data were obtained from human studies alone for eltanolone, minaxolone, ORG 21465, ORG 25435, methohexital, ketamine, and clomethiazole; for thiopental, propofol, and alphaxalone, data from both the man and the dog, and for R-etomidate, from the man, dog, and pig. Data for pentobarbital and thiamylal were obtained from the dog. The free drug concentrations associated with a 20% decrease in MAP for alphaxalone were 0.28 mM (man) and 0.10 mM (dog); for propofol, 0.34 mM (man) and 0.84 mM (dog); for thiopental, 50.1 mM (man) and 40.05 mM (dog); and for R-etomidate, 1.86 mM (man), 4.23 mM (dog), and 2.26 mM ( pig).
The final CoMFA model for cardiovascular depression (expressed as dMAP 20 ), using data for 12 i.v. anaesthetic agents, was based on a single latent variable. It showed good performance characteristics: r 2 0.958 (F 1,10 ¼ 227.841, P,0.0001), q 2 0.824, and mCV4q 2 0.808 (0.016) with a range of values 0.786 -0.835. The mean absolute log residual (calculated as predicted -observed pLog) was 0.153 (SD 0.167), with propofol being an outlier (with an absolute log residual, 0.643, being greater than 3 SDs from the mean value; Fig. 1 (Fig. 1) .
There was a significant correlation between immobilizing activity [expressed as -log (EC 50 ) and cardiovascular depression (2log MAP 20 show the spatial distribution of regions where molecular bulk is favoured (green) or disfavoured (magenta) for high anaesthetic potency or cardiovascular depression. Qualitative comparison of the two sets of maps shows three common positive favoured and one common negative favoured electrostatic areas. One bulk-favoured area is common to both pharmacophore models.
Development of pharmacophoric maps for cardiovascular depression for high anaesthetic potency are shown in red, and where positive potential is favoured in blue; while areas where molecular bulk is favoured are shown in green. Several of the key regions identified in the cardiovascular depression model are also present in the pharmacophore maps for immobilizing activity. There are electrostatic and steric regions common to both models. There are also additional negative potential regions and a steric-favoured region in the immobilizing activity model. Furthermore, there are some spatial conflicts between a bulk-favoured region in the immobilizing activity pharmacophore and a bulkdisfavoured region in the cardiovascular depression model. For comparison of pharmacophoric maps, a method of assessing how many lattice points are equivalent was adopted (i.e. the number of points that have SDÂcoefficient values of the same sign on both maps and so represent points where steric or electrostatic interactions are favoured or disfavoured in both models-but not favoured in one model and disfavoured in the other).
A quantitative comparison of the whole CoMFA grids in the two models revealed 72.16% of equivalent points for electrostatic fields and 70.89% for steric fields. When isocontours were constructed linking lattice points making the greatest 40% of the individual positive and negative contributions to each activity model, there were 87.57% of equivalent electrostatic points and 86.16% steric points for cardiovascular depression and immobilizing activities. The remaining 12.43% and 13.84% of the electrostatic and steric key regions represent areas of spatial conflict in the molecular bases of the two activity models.
The relative contributions of electrostatic and steric interactions were similar in the two activity models, with a ratio of 1.6:1 for both models (dMAP 20 : electrostatic 62.3%, steric 37.7%; immobilizing activity: electrostatic 61.8%, steric 38.2%).
Discussion
This paper has examined the molecular basis for two different activities of a diverse group of i.v. anaesthetic agents-first, anaesthetic potency and secondly, the cardiovascular effects (measured as a decrease in MAP) during continuous infusion in the absence of noxious stimulation. For both of these endpoints, separate CoMFA models have been formulated and comparison was made between the models using electrostatic and steric isocontour analysis.
When given by continuous infusion, all i.v. anaesthetic agents, with exception of ketamine, are associated with a decrease in arterial pressure and cardiac output. There is a variable response in terms of heart rate (as some studies have shown infusions of propofol to reset baroreceptor sensitivity, while other drugs maintain the expected relationship between arterial pressure and heart rate). A direct relationship between concentration and drug effect is not evident for all drugs used in continuous i.v. anaesthesia. However, the sequential dose-response studies of Prys-Roberts and colleagues with infusions of methohexital, propofol, minaxolone citrate, and Althesin (as reported by Sear 38 ) have shown dose-and concentration-related cardiovascular depressant effects.
This study used CoMFA analysis to derive pharmacophoric models for a group of structurally diverse agents. We have previously discussed the limitations of this approach and pointed out that our model for immobilization was a poorer predictor for the activities of eltanolone (the lead structure) and propofol than the other 12 agents. 2 In the potency model described in this paper, the ketamine enantiomers were excluded, but eltanolone still had the highest absolute residual. However, it appears less of an outlier than in our previous study. 2 There was substantial commonality in the molecular bases of immobilization and cardiovascular depression by the 12 i.v. anaesthetics (ketamine apart). Both CoMFA models showed some similarities and some differences. Examination of the pharmacophores shows similar spatial distributions of positive-and negative-charged regions, and bulk-favoured and -disfavoured areas. There are, however, some electrostatic and steric regions which represent areas of spatial conflict in the molecular basis of these two activities. Apart from these minor differences, we have been unable to identify any key features in the pharmacophore for cardiovascular depression which are not present in the map for immobilizing activity. This may indicate that these two pharmacological properties of i.v. anaesthetic agents are linked one to the other. However, as we found when comparing the pharmacophore maps of a series of aromatic volatile anaesthetic agents for their N-methyl-D-aspartate (NMDA) receptor inhibiting potencies and immobilizing activities, 39 these small differences may be important in defining the effects of the agents on different physiological systems.
Both models show high q 2 values. The data for immobilizing activity as reported previously indicated a good predictive model, 2 and this has been confirmed in the present study with a predictive ability of q 2 ¼0.823. Eltanolone is still one of the compounds with the highest absolute log residual, together with alphaxalone and R-etomidate. However, all are less than in our earlier paper. 2 The present study uses a different model-fitting approach for the alignment of the individual chemical entities. Whereas we previously aligned all compounds to a single-lead structure according to their Carbo indices with the anaesthetics divided into a training set to derive the model, and a test set to validate it, both models in this paper were developed using an all-in field minimization approach to achieve the best correlations between the electrostatic and steric fields of the different i.v. anaesthetics. The comparable pharmacophores and predictive indices suggest that the models are robust and have not been reached by chance iterations. Furthermore, the pharmacophore map for immobilization shows similarities to that for propofol alone in its alignment in the paper from Brown and colleagues. 40 
Sear
The cardiovascular model using the same lead conformer of eltanolone as previously gave very similar results to an earlier preliminary model which was based on molecular similarity indices but to a different lead compound-ORG 21465, where the r 2 was 0.918, q 2 0.623, F 1,6 67.276, 41 so adding further support to the robustness of the present derived cardiovascular pharmacophore.
Since the similarities of the two pharmacophore maps for immobilization and cardiovascular depression (as measured as the dMAP 20 ) suggest they may have common molecular bases, it may indicate that it will be difficult to separate the molecular features describing potency and cardiovascular depression.
Taken together, these data may infer that the decrease in MAP seen during continuous infusion anaesthesia with the other i.v. agents is partly mediated through GABAergic mechanisms. The i.v. anaesthetics (ketamine apart) all affect central sympathetic neural outflow. This originates mainly from a group of neurones in the rostral ventrolateral medulla, with changes in cardiovascular reflexes and central descending changes in sympathetic nerve activity and arterial pressure relayed through these neurones. The neurones are normally under tonic inhibition largely mediated by GABA activity at GABA A receptors. Blockade of these receptors increases baseline activity and hence increases sympathetic nerve activity and arterial pressure. 42 Increased GABA activity will therefore lead to decreased sympathetic outflow and contribute to a decrease in arterial pressure.
This study has focused on a group of i.v. agents known to interact with GABA A receptors. These are also the site of interaction of other agents (including the volatile halogenated ethers and alkanes). 43 Generation of a composite pharmacophore incorporating the effects of both i.v. and volatile agents has not been attempted. The significant charge associated with halogen atoms has previously prevented us combining halogenated and non-halogenated volatile anaesthetic agents into a single model. 4 Other sites of action for i.v. and volatile agents include the NMDA receptor, the 2P-domain potassium channels, and the neuronal nicotinic acetylcholine (nAcH) receptor. Putzke and colleagues 44 showed a differential effect of volatile and i.v. anaesthetics on the 2P-domain potassium channels-the i.v. agents propofol and etomidate have no effects at clinical concentrations, while clinical concentrations of the halogenated volatile agents inhibited the channels. Whether there is any association between interactions at these and other receptors or channels (such as the neuronal nAcH receptor) and cardiovascular depression has not been studied to date.
We excluded ketamine from the data analysis as this agent (when formulated both as the racemate and as the separate enantiomers) is associated in vivo with an increase in MAP during continuous infusion anaesthesia. This may relate to the putative mechanism of action of the phencyclidine which mediates its anaesthetic effects via the NMDA receptor. There is evidence that ketamine acts to cause sympatho-neural and sympatho-adrenal activation with inhibition of neuronal and extraneuronal catecholamine uptake. Other studies show that when co-administered with one of the benzodiazepines (which are also GABA A agonists), there is an obtunding of the arterial pressure response. 45 However, the cardio-stable effects of ketamine appear not to be unique to this phencyclidine; as similar haemodynamic conditions are seen with xenon (another NMDA receptor antagonists). 46 In conclusion, both models show that molecular bulk and electrostatic potential are important determinants of i.v. anaesthetic activities. The similarities between the pharmacophoric maps for cardiovascular depression and immobilizing activity suggest that pharmaceutical attempts to separate these properties of the agents may be difficult to achieve.
